Phase II study of zolbetuximab plus pembrolizumab in claudin 18.2: Positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)—ILUSTRO Cohort 3.
作者： Eric Van Cutsem , Peter C. Enzinger , Daniel V.T. Catenacci , David H. Ilson , Jaffer A. Ajani
DOI: 10.1200/JCO.2021.39.3_SUPPL.TPS260
关键词:
摘要: TPS260Background: Five-year survival with advanced G/GEJ is poor, and limited biomarkers exist to inform optimal treatment selection. Pembrolizumab, an anti–programmed death-1 receptor (PD-1) antib...
sci-hub.st 参考文章(0)